Tango Therapeutics, Inc.

BCTG Acquisition Corp. (Nasdaq: BCTG) was a blank-check company sponsored by Boxer Capital, a healthcare-focused investment firm, that completed its initial public offering in 2020. The vehicle targeted the healthcare sector and announced a business combination with Tango Therapeutics, Inc., a precision oncology biopharmaceutical company, on April 14, 2021. Tango Therapeutics applies a CRISPR-based functional genomics platform to identify and drug cancer-specific synthetic lethal vulnerabilities. The transaction closed and Tango Therapeutics began trading on Nasdaq under the ticker TNGX, with BCTG now carrying a closed status. For complete deal terms, filing history, and sponsor data on BCTG and comparable healthcare SPACs, create a free account at SpacDesk.

SPAC Counterparty (1)